Kinetics and performance of the Abbott architect SARS-CoV-2 IgG antibody assay
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.07.03.20145722: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: These two groups were recruited prospectively in to the DISCOVER study at North Bristol NHS Trust for which HRA Approval was granted by the South Yorkshire Research Ethics Committee (20/YH/0121). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Serum or plasma samples were collected at various time points during in-patient and out-patient follow-up (Appendix 1) The third group consisted of 114 healthcare workers at North Bristol NHS Trust who tested SARS-CoV-2 PCR positive during investigation of suspected COVID-19, and from whom serum or plasma … SciScore for 10.1101/2020.07.03.20145722: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: These two groups were recruited prospectively in to the DISCOVER study at North Bristol NHS Trust for which HRA Approval was granted by the South Yorkshire Research Ethics Committee (20/YH/0121). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Serum or plasma samples were collected at various time points during in-patient and out-patient follow-up (Appendix 1) The third group consisted of 114 healthcare workers at North Bristol NHS Trust who tested SARS-CoV-2 PCR positive during investigation of suspected COVID-19, and from whom serum or plasma samples were tested for SARS-CoV-2 antibody as part of NHS England’s healthcare workers testing programme. SARS-CoV-2suggested: NoneSoftware and Algorithms Sentences Resources Study design: This study aimed to estimate the kinetics of the antibody response (i.e time taken to seroconvert) with the Abbott Architect SARS-CoV-2 IgG antibody assay, and estimate the sensitivity of this assay. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Statistical approach: The sensitivity of the Abbott SARS-CoV-2 IgG assay was estimated with 95% Confidence Intervals at different time points post symptom onset (DISCOVER patients) or first PCR positive result (healthcare workers). Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: Thank you for sharing your code and data.
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strengths and weaknesses: The major strength of our cohort is the size, and the inclusion of milder patients that have been absent in many previous studies, and are a recommendation of a recent Cochrane review.7 As the clinical use of antibody testing is likely to be in patients without hospitalisation, this data is invaluable. All previous papers except one have had limited clinical information or focused entirely on hospitalised patients, limiting extrapolation to other clinical settings. Secondly, We had a systematic approach to testing our patient cohort recruiting both proven and strongly suspected cases in a consecutive manner, limiting bias. We also collected detailed clinical metadata on our patient cohort, allowing us to look for patient level differences in antibody response. Finally, anonymised data including the index cut-off is available from our paper, to rapidly allow meta-analysis with other cohorts. One weakness of our paper is our limited data on healthcare worker clinical information. Due to data protection concerns, we did not have access to individual data, although to our knowledge very few healthcare workers locally had severe disease, so they are likely to represent a cohort of milder disease. To our knowledge, less than five healthcare workers were admitted during the study period, suggesting this cohort can be extrapolated to those with milder disease. Implications: This paper suggests the sensitivity of the Abbott Architect IgG assay, a PHE approved...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
